The Libre Duo. A platform prototype to move care from the hospital to the home?

01/06/2026 admin 0

Abbott has put glucose and ketones on the same wearable, and the launch coverage is all about DKA. Worth having if you’re on a pump, which is fine as far as it goes, but it misses the bit that makes this interesting. Because if you look at what Abbott has actually built across its other divisions, and what they’ve patented alongside it, the Libre Duo doesn’t really look like a ketone sensor. It looks like the platform prototype and the first visible piece of an infrastructure designed to move chronic disease care out of outpatients and into the home. And the policy environment for that shift has just been locked in on both sides of the Atlantic for the next five years.

100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure

03/03/2026 admin 2

Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn’t it a cure yet, and how does it fit into the actual blueprint of a functional cure?

Explore a Decade of Diabetes Insights with Diabettech AI

25/02/2026 admin 3

After 10+ years of documenting the diabetes landscape, Diabettech is launching diabettech.ai—a custom research tool designed to help you navigate a decade’s worth of articles and reports. Powered by an LLM interface, this tool allows you to “interrogate” the site’s data to find specific answers on everything from cures to n=1 observations.
​Key highlights of the beta launch:
​Targeted Accuracy: Built to stick strictly to Diabettech articles and comments to minimize “hallucinations.”
​Research-Focused: Optimized as a precision tool rather than a standard chatbot to provide relevant article links.
​Sustainable Design: Privately funded and optimized for efficiency to manage resource costs and query speeds.
​Ready to dive into the archives? Visit diabettech.ai to start your research and share your feedback on the beta experience.